{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:48:20Z","timestamp":1793915300860,"version":"4.8.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Pretreatment predictions of absorbed doses can be especially valuable for patient selection and dosimetry-guided individualization of radiopharmaceutical therapy. Our goal was to build regression models using pretherapy\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE PET uptake data and other baseline clinical factors\/biomarkers to predict renal absorbed dose delivered by\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTATATE peptide receptor radionuclide therapy (\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PRRT) for neuroendocrine tumors. We explore the combination of biomarkers and\n                      <jats:sup>68<\/jats:sup>\n                      Ga PET uptake metrics, hypothesizing that they will improve predictive power over univariable regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Pretherapy\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE PET\/CTs were analyzed for 25 patients (50 kidneys) who also underwent quantitative\n                      <jats:sup>177<\/jats:sup>\n                      Lu SPECT\/CT imaging at approximately 4, 24, 96, and 168 hours after cycle 1 of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PRRT. Kidneys were contoured on the CT of the PET\/CT and SPECT\/CT using validated deep learning\u2013based tools. Dosimetry was performed by coupling the multi\u2013time point SPECT\/CT images with an in-house Monte Carlo code. Pretherapy renal PET SUV metrics, activity concentration per injected activity (Bq\/mL\/MBq), and other baseline clinical factors\/biomarkers were investigated as predictors of the\n                      <jats:sup>177<\/jats:sup>\n                      Lu SPECT\/CT-derived mean absorbed dose per injected activity to the kidneys using univariable and bivariable models. Leave-one-out cross-validation (LOOCV) was used to estimate model performance using root mean squared error and absolute percent error in predicted renal absorbed dose including mean absolute percent error (MAPE) and associated standard deviation (SD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median therapy-delivered renal dose was 0.5 Gy\/GBq (range, 0.2\u20131.0 Gy\/GBq). In LOOCV of univariable models, PET uptake (Bq\/mL\/MBq) performs best with MAPE of 18.0% (SD = 13.3%), and estimated glomerular filtration rate (eGFR) gives an MAPE of 28.5% (SD = 19.2%). Bivariable regression with both PET uptake and eGFR gives LOOCV MAPE of 17.3% (SD = 11.8%), indicating minimal improvement over univariable models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Pretherapy\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE PET renal uptake can be used to predict post-\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PRRT SPECT-derived mean absorbed dose to the kidneys with accuracy within 18%, on average. Compared with PET uptake alone, including eGFR in the same model to account for patient-specific kinetics did not improve predictive power. Following further validation of these preliminary findings in an independent cohort, predictions using renal PET uptake can be used in the clinic for patient selection and individualization of treatment before initiating the first cycle of PRRT.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004599","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:06:53Z","timestamp":1680520013000},"page":"393-399","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["177Lu-DOTATATE Theranostics"],"prefix":"10.1097","volume":"48","author":[{"given":"Avery B.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Muzik","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Wayne State University, Detroit, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Schipper","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuni K.","family":"Dewaraja","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","article-title":"Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.121.262069","article-title":"Dosimetric quantities in neuroendocrine tumors over treatment cycles with 177Lu-DOTATATE","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"bib4-20250621","first-page":"97S","article-title":"Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive?","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/RLU.0000000000003412","article-title":"Clinical assessment of 177Lu-DOTATATE quantification by comparison of SUV-based parameters measured on both post-PRRT SPECT\/CT and 68Ga-DOTATOC PET\/CT in patients with neuroendocrine tumors: a feasibility study","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/MNM.0000000000001592","article-title":"Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors","volume":"43","year":"2022","journal-title":"Nucl Med Commun"},{"key":"bib7-20250621","first-page":"1366","article-title":"Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software","volume":"45","year":"2004","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00259-012-2124-x","article-title":"PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma","volume":"39","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0b013e31823926e5","article-title":"Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?","volume":"37","year":"2012","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","article-title":"[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib15-20250621","first-page":"1665","article-title":"A pipeline for automated voxel dosimetry: application in patients with multi-SPECT\/CT imaging after 177Lu-peptide receptor radionuclide therapy","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","article-title":"The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy","volume":"39","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib19-20250621","first-page":"170","article-title":"Markers of renal function tests","volume":"2","year":"2010","journal-title":"N Am J Med Sci"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"e0177971","DOI":"10.1371\/journal.pone.0177971","article-title":"An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value","volume":"12","year":"2017","journal-title":"PLos One"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia","volume":"162","year":"2002","journal-title":"Arch Intern Med"},{"key":"bib22-20250621","first-page":"1452","article-title":"Bone marrow hypocellularity in patients with end-stage kidney disease","volume":"9","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/ndt\/gfr267","article-title":"Uremia induces functional incompetence of bone marrow\u2013derived stromal cells","volume":"27","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.118.211094","article-title":"Characterization of noise and resolution for quantitative 177Lu SPECT\/CT with xSPECT quant","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1002\/mp.12586","article-title":"Voxel-based multimodel fitting method for modeling time activity curves in SPECT images","volume":"44","year":"2017","journal-title":"Med Phys"},{"issue":"S37","key":"bib26-20250621","first-page":"63","article-title":"MO106: circulating neutrophil count is associated with severity of chronic kidney disease","volume":"37","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2967\/jnumed.121.261906","article-title":"Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality?","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"55094","DOI":"10.18632\/oncotarget.19049","article-title":"Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s11307-018-1293-9","article-title":"Impact of tumor burden on quantitative [68Ga] DOTATOC biodistribution","volume":"21","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/0284186X.2017.1378431","article-title":"Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance","volume":"57","year":"2018","journal-title":"Acta Oncol"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2967\/jnumed.120.256255","article-title":"A novel time-activity information-sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT\/CT after 177Lu-DOTATATE","volume":"62","year":"2021","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T15:02:13Z","timestamp":1750518133000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004599"}},"subtitle":["Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers"],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004599","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,8]]}}}